Dickson G.J.,University College London |
Dickson G.J.,Kings College London |
Bustraan S.,University College London |
Hills R.K.,University of Cardiff |
And 7 more authors.
British Journal of Haematology | Year: 2016
Older adult patients (≥60 years) with acute myeloid leukaemia (AML) are generally considered to be poor-risk and there is limited information available regarding risk stratification based on molecular characterization in this age group, particularly for the double-mutant CEBPA (CEBPADM) genotype. To investigate whether a molecular favourable-risk genotype can be identified, we investigated CEBPA, NPM1 and FLT3 status and prognostic impact in a cohort of 301 patients aged 60 years or more with intermediate-risk cytogenetics, all treated intensively. Overall survival (OS) at 1 year was highest in the 12 patients (4%) that were CEBPADM compared to the 76 (28%) with a mutant NPM1 and wild-type FLT3 (NPM1MUTFLT3WT) genotype or all other patients (75%, 54%, 33% respectively), with median survival 15·2, 13·6 and 6·6 months, although the benefit was short-term (OS at 3 years 17%, 29%, 12% respectively). Combination of the CEBPADM and NPM1MUTFLT3WT genotype patients defined a molecular group with favourable prognosis (P < 0·0001 in multivariate analysis), with 57% of patients alive at 1 year compared to 33% for all other patients. Knowledge of genotype in older cytogenetically intermediate-risk patients might influence therapy decisions. © 2016 John Wiley & Sons Ltd. Source
EmeraMed Ltd, Nbmi and CTI Science | Date: 2014-09-02
Pharmaceutical preparations for humans and veterinary pharmaceutical preparations for the treatment of heavy metal toxicity and oxidative stress; sanitary preparations for medical purposes; Dietetic substances, namely, sugar substitutes for medical or veterinary use; food for babies; dietary supplements for humans and animals; medical plasters and dressings; material for stopping teeth; dental wax; disinfectants for sanitary purposes; preparations for destroying vermin; fungicides and herbicides.
CTI Science | Date: 2008-10-10
Antioxidants and proteins used in the manufacture of cosmetics, beverages, food products and food supplements.
ERMES MEDICAL COMPANY Ltd and CTI Science | Date: 2009-11-17
Amelioration of acute mercury toxicity by a novel, non-toxic lipid soluble chelator N,N′bis-(2-mercaptoethyl)isophthalamide: Effect on animal survival, health, mercury excretion, and organ accumulation
Clarke D.,Arkansas State University |
Buchanan R.,Arkansas State University |
Gupta N.,University of Kentucky |
Gupta N.,CTI Science |
And 2 more authors.
Toxicological and Environmental Chemistry | Year: 2012
The toxic effects of mercury are known to be complex with specific enzyme inhibitions and subsequent oxidative stress adding to the damaging effects. There are likely other factors involved, such as the development of impaired metal ion homeostasis and depletion of thiol- and selenium-based metabolites such as cysteine and selenium. Much of the toxicity of mercury occurs at the intracellular level via binding of Hg 2+ to thiol groups in specific proteins. Therefore, amelioration of mercury toxicity by the use of chelation would likely be enhanced by the use of a chelator that could cross the cell membrane and the blood brain barrier. It would be most favorable if this compound was of low toxicity, had appropriate pharmacokinetics, bound and rendered mercury cation non-toxic and had antioxidant properties. Herein we report on such a chelator, N,N′-bis(2-mercaptoethyl)isophthalamide (NBMI), and, using an animal model, show that it prevented the toxic effects associated with acute exposure induced by injected mercury chloride. © 2012 Taylor and Francis Group, LLC. Source